InMed Pharmaceuticals Inc.
INM
$0.88
-$0.01-1.47%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -26.77% | -14.15% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -26.77% | -14.15% | |||
| Cost of Revenue | -11.30% | -1.52% | |||
| Gross Profit | -54.32% | -30.08% | |||
| SG&A Expenses | 5.82% | -32.01% | |||
| Depreciation & Amortization | 0.00% | 0.76% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 1.98% | -8.36% | |||
| Operating Income | -20.24% | 4.26% | |||
| Income Before Tax | -17.45% | 3.43% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -17.45% | 3.43% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -17.45% | 3.43% | |||
| EBIT | -20.24% | 4.26% | |||
| EBITDA | -20.87% | 4.41% | |||
| EPS Basic | -65.63% | 63.56% | |||
| Normalized Basic EPS | -65.67% | 63.56% | |||
| EPS Diluted | -65.63% | 63.56% | |||
| Normalized Diluted EPS | -65.67% | 63.56% | |||
| Average Basic Shares Outstanding | -29.09% | 165.01% | |||
| Average Diluted Shares Outstanding | -29.09% | 165.01% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||